根治性切除术后 IIIA-N2 期非小细胞肺癌男性患者可能从术后放疗中获益：基于人群的生存分析。
Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis.
机构信息
Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.
Department of internal Medicine-Oncology, Shandong Cancer Hospital & Institute, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, PR China.
出版信息
Future Oncol. 2018 Oct;14(23):2371-2381. doi: 10.2217/fon-2018-0326. Epub 2018 May 29.
AIM
Our analysis was performed to assess the efficacy of postoperative radiotherapy (PORT) on the survival for pathologic IIIA-N2 Non-small-cell lung cancer patients.
PATIENTS & METHODS: We identified 2949 patients from 2004 to 2013 in the SEER database. Propensity score-matching was used to reduce the selection bias. Overall survival (OS), cancer-specific survival (CSS) and the factors associated with survival prognosis were evaluated.
RESULTS
There was no significant difference in OS and CSS between PORT and non-PORT groups. However, subgroup analysis revealed an OS (p = 0.007) and CSS (p = 0.006) detrimental for male patients not receiving PORT. Multivariate analysis showed that old age, male sex, high pathologic grade, squamous carcinoma, bigger tumor size and larger number of positive lymph nodes had a negative impact on survival.
CONCLUSION
PORT could improve OS and CSS in male patients with resected IIIA-N2 non-small-cell lung cancer.
目的
我们的分析旨在评估术后放疗（PORT）对病理 IIIA-N2 期非小细胞肺癌患者生存的疗效。
患者与方法
我们从 SEER 数据库中确定了 2004 年至 2013 年间的 2949 名患者。采用倾向评分匹配法来减少选择偏差。评估了总生存期（OS）、癌症特异性生存期（CSS）以及与生存预后相关的因素。
结果
PORT 组与非 PORT 组之间的 OS 和 CSS 无显著差异。然而，亚组分析显示，未接受 PORT 的男性患者 OS（p=0.007）和 CSS（p=0.006）更差。多因素分析表明，年龄较大、男性、高病理分级、鳞状细胞癌、肿瘤较大和阳性淋巴结数量较多对生存有负面影响。
结论
PORT 可改善接受手术切除的 IIIA-N2 期非小细胞肺癌男性患者的 OS 和 CSS。
Zotero 插件